Imaging‑Based Diagnosis and Biopsy Decision‑Making for Hepatocellular Carcinoma in Cirrhotic Patients

≥ 2 cm Nodules with Typical Imaging Features

In a cirrhotic patient with a solitary liver nodule ≥ 2 cm that shows arterial‑phase hyperenhancement and portal‑venous washout on multiphasic CT or MRI, a biopsy is not required because the lesion can be confidently diagnosed as HCC on imaging alone. 1
A single multiphasic CT or MRI study demonstrating the characteristic HCC hallmarks (arterial‑phase hyperenhancement followed by washout in the portal‑venous or delayed phases) provides definitive diagnosis without the need for tissue sampling. 3
This imaging‑only strategy yields a specificity of 91 %–100 %, offering very high diagnostic confidence. 1
Biopsy should be reserved for cases where the imaging appearance is atypical or the vascular profile does not match classic HCC criteria. 4

Because imaging sensitivity is lower for lesions 1–2 cm, a more conservative diagnostic pathway is recommended. 1
Diagnosis should be based on two concordant imaging studies (e.g., CT + MRI) that both display the typical HCC pattern before a definitive diagnosis is made. 4
If imaging findings are non‑characteristic or discordant between modalities, a percutaneous biopsy is indicated. 3
The sensitivity of imaging for 1–2 cm lesions ranges from 41 % to 62 %, compared with 65 %–89 % for lesions ≥ 2 cm. 1

Immediate biopsy is not recommended; instead, perform surveillance with ultrasound every 3–6 months. 3
When the nodule remains stable for 12 months, patients can return to routine six‑monthly surveillance. 3
If growth is detected, re‑evaluate the lesion using the algorithm appropriate for its new size category. 4

Atypical imaging – lesions lacking the classic arterial‑phase hyperenhancement with washout pattern. 1
Non‑cirrhotic or non‑high‑risk patients – imaging criteria are validated only for patients with cirrhosis, chronic hepatitis B, or chronic hepatitis C. 1
Targetoid appearance or marked T2 hyperintensity – features that raise suspicion for non‑HCC malignancies. 1
Discordant imaging results – conflicting findings across different imaging modalities. 3
Need for absolute diagnostic certainty – when treatment decisions require confirmation because imaging alone carries a 5 %–10 % false‑positive rate. 3

Needle‑tract seeding occurs in only 1 %–3 % of procedures and does not impact overall survival. 3
Bleeding complications are infrequent and generally manageable. 3
These low‑risk profiles should not deter biopsy when it is clinically indicated. 3

If biopsy results are negative yet imaging remains suspicious, schedule close follow‑up with imaging every 3–6 months. 3
Perform a repeat biopsy if the lesion enlarges or its enhancement pattern changes during surveillance. 3
Be aware that false‑negative biopsies are more common in small lesions. 3